A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma of the head and neck but in patients with recurrent or metastatic disease, EGFR targeting agents have displayed modest efficacy. Vascular endothelial growth factor (VEGF) mediated angiogenesis ha...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cohen, Ezra EW, Davis, Darren W., Karrison, Theodore G, Seiwert, Tanguy Y., Wong, Stuart J., Nattam, Sreenivasa, Kozloff, Mark F., Clark, Joseph I., Yan, Duen-Hwa, Liu, Wen, Pierce, Carolyn, Dancey, Janet E, Stenson, Kerstin, Blair, Elizabeth, Dekker, Allison, Vokes, Everett E
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768532/
https://ncbi.nlm.nih.gov/pubmed/19201650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(09)70002-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados